reports
Initiation: Building up therapeutics assets
Amarantus has acquired several pre-commercial therapeutic assets in recent years, and intends to create value by furthering their development before out-licensing or commercialising them. The firm recently acquired ESS-W, which can shorten the time needed to treat severe burns. Eltoprazine aims to reduce involuntary movements associated with long-term levodopa therapy in Parkinson’s disease. These candidates provide long-term potential, and drive our $76m rNPV.
QuickView: Expanding into regenerative medicine
Amarantus entered into an option agreement with Lonza to acquire its engineered skin substitute (ESS) platform for the treatment of severe burns. It plans to start a 10-pt Phase I/II study in Q215, which could lead to launch by 2018, in a c $500m US severe burn market. The firm also plans to launch LymPro as a laboratory-developed test for Alzheimer’s disease (AD) in Q414. MANF and Eltoprazine also provide value driver opportunities.
QuickView: Potential of LymPro indicated
Amarantus presented data of its blood-based diagnostic test for Alzheimer’s disease (AD), LymPro, at the Alzheimer’s Association International Conference (AAIC). Data from a 41-patient trial with an optimised test showed a specificity of 81% and a sensitivity of 73%. Commercial launch of LymPro as a laboratory-developed test remains on track for H214. MANF has also started formal preclinical testing and could begin clinical development in 2015. Eltoprazine is expected to start a Phase IIb tr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.